EGFR and non-small cell lung carcinoma: Recent studies of NSCLC patients treated with pembrolizumab showed a different mutation burden [10, 12] and that immunogenicity of EGFR-mutant tumors could be increased with combination treatments [13] but more trials are required to confirm this finding.